Dazukibart

达组奇拜单抗

Report date: 2026/05/16 20:00:17

Base Information

Drug NameDazukibart
Drug Alias NameAnti-Beta InterferonPF-06823859
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunomodulatorsInterferon beta inhibitors
TargetsInterferon beta
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Erythematosus, CutaneousDermatomyositis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncWyeth BioPharma Division of Wyeth Pharmaceuticals LlcPfizer Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatomyositisPolymyositisMyositis +[4] 
Inactive IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous

Other Information

ATC CodeN/A
Related LinksN/A